Skip to search formSkip to main contentSkip to account menu

GSK1325756

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract Background Excessive neutrophil migration has been correlated with influenza symptom severity. Danirixin (GSK1325756), a… 
2018
2018
  • N. Gross
  • Chronic obstructive pulmonary diseases
  • 2018
  • Corpus ID: 4707345
From the GlaxoSmithKline trial of danirixin: “The inflammation associated with chronic obstructive pulmonary disease (COPD) is… 
2017
2017
Background: Danirixin (DNX) is a competitive, reversible CXCR2 chemokine receptor antagonist. CXCR2 antagonists inhibit… 
2015
2015
BackgroundExcessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases. The… 
2014
2014
Danirixin (GSK1325756) is a small, high-affinity, selective and reversible CXCR2 antagonist in development for treatment of… 
2013
2013
Characterization of the biliary disposition of GSK1325756, using a non‐invasive bile sampling technique and spectrometric…